FDA Investigates Cancer Risk Linked to Novartis' Zolgensma Gene Therapy
The FDA is investigating cancer risk associated with Novartis' Zolgensma gene therapy.
BASEL (dpa-AFX) - In medicine, one truth transcends time: a drug's worth is measured not merely by how effectively it fights disease, but also by how safely it does so.One medicine that has recently drawn the FDA's attention over emerging safety concerns is Novartis Inc.'s (NVS) Zolgensma gene ther…